Medidata reaches into South Korea with a CRO partnership

South Korean CRO C&R Research is adopting Medidata's ($MDSO) eClinical technology for its trials throughout Asia, striking a partnership to bolster its data analysis technology in a fast-growing market.

Under the deal, C&R will implement Medidata's services for electronic data capture and risk-based monitoring for its work running studies around the region, a move the CRO said will help it speed up trial execution and cut costs for clients. C&R is adopting Medidata Rave, a cloud-based technology for gathering and storing patient data, and Medidata RBM, which allows the CRO to take a bird's-eye view of multiple sites to identify potential risks.

C&R, which bills itself as South Korea's first CRO, is working to stand out in a growing market, and bringing in Metadata's technology is its latest effort to burnish its offerings, company President Moon Tae Yoon said.

"South Korea has quickly become a key hub for multinational clinical trials, and we at C&R are committed to ensuring we support our local and global biopharmaceutical customers' R&D programs with the most innovative technologies," Yoon said in a statement.

The CRO got off the ground in 1997, gradually expanding across Asia and North America through partnerships with Oracle, INC Research ($INCR) and others. C&R's client roster boasts multinational pharma companies including GlaxoSmithKline ($GSK) and Novartis ($NVS).

Medidata has become an in-demand partner among the world's largest CROs, counting among its clients PPD, Icon ($ICLR), INC Research and Quintiles ($Q). The company's know-how in adaptive clinical trials also lured TransCelerate BioPharma, a consortium of the world's largest drugmakers, which recruited Medidata to help it convince its members to embrace risk-based monitoring.

- read the statement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.